CA3179754A1 - Cyclobenzaprine treatment for sexual dysfunction - Google Patents
Cyclobenzaprine treatment for sexual dysfunctionInfo
- Publication number
- CA3179754A1 CA3179754A1 CA3179754A CA3179754A CA3179754A1 CA 3179754 A1 CA3179754 A1 CA 3179754A1 CA 3179754 A CA3179754 A CA 3179754A CA 3179754 A CA3179754 A CA 3179754A CA 3179754 A1 CA3179754 A1 CA 3179754A1
- Authority
- CA
- Canada
- Prior art keywords
- cyclobenzaprine
- agent
- pharmaceutically acceptable
- combination
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063007251P | 2020-04-08 | 2020-04-08 | |
| US63/007,251 | 2020-04-08 | ||
| PCT/US2021/026492 WO2021207561A1 (en) | 2020-04-08 | 2021-04-08 | Cyclobenzaprine treatment for sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3179754A1 true CA3179754A1 (en) | 2021-10-14 |
Family
ID=75675042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3179754A Pending CA3179754A1 (en) | 2020-04-08 | 2021-04-08 | Cyclobenzaprine treatment for sexual dysfunction |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210315841A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4132648B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7780447B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115803088B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021253592A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179754A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021207561A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240415789A1 (en) * | 2021-10-06 | 2024-12-19 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| US12370198B2 (en) | 2022-07-08 | 2025-07-29 | La Pharmatech Inc | Pharmaceutical compositions and methods for treating psychiatric disorders |
| KR20250086333A (ko) * | 2023-12-06 | 2025-06-13 | 삼진제약주식회사 | 약학적 제제 및 이의 제조방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| AR025110A1 (es) * | 1999-08-13 | 2002-11-06 | Vela Pharmaceuticals Inc | Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina |
| US6855324B2 (en) * | 2000-11-20 | 2005-02-15 | Adrian Sandler | Therapeutic placebo enhancement of commonly-used medications |
| JP2008540673A (ja) * | 2005-05-19 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤誘発性性機能不全の治療方法 |
| PT2501234T (pt) * | 2009-11-20 | 2017-12-13 | Tonix Pharma Holdings Ltd | Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina |
| EA201391459A1 (ru) | 2011-04-04 | 2014-03-31 | С1 Биофарма, Инк. | Режимы лечения |
| SI2861223T1 (sl) * | 2012-06-15 | 2023-01-31 | Tonix Pharma Holdings Limited | Sestavki in postopki za transmukozalno absorpcijo |
| MY196014A (en) * | 2013-03-15 | 2023-03-06 | Tonix Pharmaceuticals Inc | Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride |
| SG10201902203VA (en) * | 2014-09-18 | 2019-04-29 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| JP2018512450A (ja) * | 2015-03-19 | 2018-05-17 | ウェンディ アン エプスタインEPSTEIN, Wendy Anne | 女性の性的障害を治療するための化合物及び剤型 |
| MX2019005851A (es) * | 2016-11-22 | 2019-10-07 | Alkalidx Inc | Terapias para el tratamiento de afecciones hipocalemicas e ineficaces a lidocaina. |
| BR112020011345A2 (pt) | 2017-12-11 | 2020-11-17 | Tonix Pharma Holdings Limited | tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas |
| EP3840738A1 (en) | 2018-08-20 | 2021-06-30 | Tonix Pharma Holdings Limited | Methods of treating acute stress disorder and posttraumatic stress disorder |
| US11337937B2 (en) * | 2018-08-27 | 2022-05-24 | ReJoy | TARR receptor agonists for sexual dysfunction |
-
2021
- 2021-04-08 JP JP2022562023A patent/JP7780447B2/ja active Active
- 2021-04-08 EP EP21721779.3A patent/EP4132648B1/en active Active
- 2021-04-08 WO PCT/US2021/026492 patent/WO2021207561A1/en not_active Ceased
- 2021-04-08 CA CA3179754A patent/CA3179754A1/en active Pending
- 2021-04-08 US US17/226,058 patent/US20210315841A1/en active Pending
- 2021-04-08 CN CN202180040673.8A patent/CN115803088B/zh active Active
- 2021-04-08 AU AU2021253592A patent/AU2021253592A1/en active Pending
-
2025
- 2025-10-14 JP JP2025172812A patent/JP2025185159A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021207561A1 (en) | 2021-10-14 |
| CN115803088A (zh) | 2023-03-14 |
| US20210315841A1 (en) | 2021-10-14 |
| EP4132648A1 (en) | 2023-02-15 |
| JP2023521167A (ja) | 2023-05-23 |
| EP4132648B1 (en) | 2026-07-08 |
| JP2025185159A (ja) | 2025-12-18 |
| CN115803088B (zh) | 2025-03-21 |
| AU2021253592A1 (en) | 2022-11-10 |
| JP7780447B2 (ja) | 2025-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220152057A1 (en) | Methods and compositions for treating various disorders | |
| US11707440B2 (en) | Esketamine for the treatment of depression | |
| JP2025185159A (ja) | 性機能障害のシクロベンザプリン処置 | |
| EP4094766A1 (en) | Methods of treating uterine fibroids and endometriosis | |
| US20250295674A1 (en) | Neuroactive steroids for treatment of cns-related disorders | |
| BRPI0709924A2 (pt) | mÉtodo para prevenir ou tratar uma condiÇço decorrente de deficiÊncia de estrogÊnio local | |
| US20220160683A1 (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| US20180280410A1 (en) | Natural combination hormone replacement formulations and therapies | |
| JP2023521167A5 (cg-RX-API-DMAC7.html) | ||
| WO2023059728A1 (en) | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients | |
| EP2758046A1 (en) | N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders | |
| HK40090080A (zh) | 性功能障碍的环苯扎林治疗 | |
| HK40090080B (en) | Cyclobenzaprine treatment for sexual dysfunction | |
| CN115379843A (zh) | 疼痛治疗用药物 | |
| US20180369257A1 (en) | Selective progesterone receptor modulators (sprm) and stabilized estrogen level in patient | |
| JP2022516482A (ja) | うつ病を処置するためのドンペリドン組成物及び方法 | |
| US20250090528A1 (en) | Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy | |
| CA3218384A1 (en) | Use of complement factor d inhibitor for treatment of generalized myasthenia gravis | |
| AU2024238367A1 (en) | Method for treating l-dopa-induced dyskinesia using befiradol | |
| WO2023159035A1 (en) | Neuroactive steroids for treatment of cns-related disorders | |
| AU2024329780A1 (en) | Elafibranor for use in the treatment of primary biliary cholangitis | |
| HK40060077A (en) | Domperidone compositions and methods for treating depression | |
| HK40103286A (en) | Methods of treating conditions related to the s1p₁ receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250324 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250331 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250408 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250408 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250408 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250505 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250505 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250505 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250520 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260319 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260319 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260504 |